Oligorecurrent Prostate Cancer and Stereotactic Body Radiotherapy: Where Are We Now? A Systematic Review and Meta-analysis of Prospective Studies
Open Access
- 1 May 2021
- journal article
- review article
- Published by Elsevier BV in European Urology Open Science
- Vol. 27, 19-28
- https://doi.org/10.1016/j.euros.2021.02.008
Abstract
No abstract availableFunding Information
- Fondazione Italiana per la Ricerca sul Cancro Airc
This publication has 30 references indexed in Scilit:
- Oligorecurrent Nodal Prostate CancerAmerican Journal of Clinical Oncology, 2018
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED TrialJournal of Clinical Oncology, 2018
- Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II TrialJournal of Clinical Oncology, 2018
- 68Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy – diagnostic performance and impact on therapeutic decision-makingEuropean Journal of Nuclear Medicine and Molecular Imaging, 2017
- Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted TherapyJournal of Nuclear Medicine, 2015
- Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases of prostate cancerUrologic Oncology, 2013
- Measuring inconsistency in meta-analysesBMJ, 2003
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986
- The Combination of Estimates from Different ExperimentsBiometrics, 1954